Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.

Related LLY
Eli Lilly Release Confirms FDA Approval If Portrazza
US Stock Futures Edge Higher Ahead Of Jobless Claims Report
Steven Cohen Hikes Stake in Microsoft by More Than 50,000% (GuruFocus)

In a report published Friday, Goldman Sachs Group reiterated its Sell rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $39.00 to $42.00.

Goldman Sachs noted, “We reiterate our Sell rating on LLY shares (relative to our Attractive coverage view on Pharma) and would take profits on recent strength driven by what we believe is a solanezumab hope-induced trade, which we see as premature. Based on our analysis, LLY shares already reflect $7 bn in Sola optionality value and a 50% probability of sola success, driven by the hint of efficacy seen in a pooled analysis of both studies in secondary endpoints. Data at ANA on Oct 8 will be a key to either supporting or significantly challenging that view. We are skeptical about a meaningful benefit and at the very best, expect that LLY will have to run another confirmatory Phase 3 clinical trial for 18 months in mild patients if the efficacy signal is based on a meaningful clinical benefit. This pushes the timeline out by 3-4 years.”

Eli Lilly & Co. closed on Thursday at $47.15.

Latest Ratings for LLY

Nov 2015BMO CapitalUpgradesMarket PerformOutperform
Oct 2015Leerink SwannMaintainsOutperform
Oct 2015Credit SuisseUpgradesNeutralOutperform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

Get Benzinga's Newsletters